- Home
- MLTX
as 01-17-2025 4:00pm EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
| Founded: | 2021 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 3.4B | IPO Year: | N/A |
| Target Price: | $84.20 | AVG Volume (30 days): | 383.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $37.55 - $64.98 | Next Earning Date: | 02-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MoonLake Immunotherapeutics News
MLTX Breaking Stock News: Dive into MLTX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62
TipRanks
9 days ago
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
MT Newswires
10 days ago
BTIG Adjusts MoonLake Immunotherapeutics' Price Target to $81 From $71, Keeps Buy Rating
MT Newswires
10 days ago
MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says
MT Newswires
10 days ago
MoonLake Immunotherapeutics Starts Three New Clinical Trials Evaluating Sonelokimab in Inflammatory Diseases
GlobeNewswire
11 days ago
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
Simply Wall St.
18 days ago
Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?
GlobeNewswire
2 months ago
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Compare MLTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.